DNA甲基化标志物在肝细胞癌检测中的应用
本文综述了DNA甲基化标志物作为新型生物标志物用于早期肝细胞癌(HCC)检测的研究进展。多项研究显示,血液甲基化DNA标志物相比现行监测方法具有更高的敏感性和特异性,但多种因素目前限制其即时应用;本文还强调肝病病因学在致癌机制中的重要性。
要点
- 甲基化DNA标志物对HCC检测具有特异性
- 血液甲基化标志物在多项研究中显示优于现行监测方法的敏感性和特异性
- 多种因素目前限制这些标志物的即时临床应用
核心结论
- 甲基化DNA标志物是有前景的早期HCC检测新型生物标志物,但多种因素目前限制其即时应用。
研究设计与样本
- 本文为综述,汇总近期关于HCC中甲基化DNA标志物的研究,并详细论证使用甲基化标志物检测HCC的依据与方法,重点讨论肝病病因学在致癌机制中的重要性。
主要发现
- 多项研究在血液中检测甲基化DNA标志物用于早期HCC,发现其敏感性和特异性优于现行监测方法。
- 研究显示甲基化DNA标志物对HCC检测可具有特异性。
局限性
- 原文指出多种因素目前限制这些标志物的即时应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and has a poor prognosis. Epigenetic modification has been shown to be deregulated during HCC development by dramatically impacting the differentiation, proliferation, and function of cells. One important epigenetic modification is DNA methylation during which methyl groups are added to cytosines without changing the DNA sequence itself. Studies found that methylated DNA markers can be specific for detection of HCC. On the basis of these findings, the utility of methylated DNA markers as novel biomarkers for early-stage HCC has been measured in blood, and indeed superior sensitivity and specificity have been found in several studies when compared to current surveillance methods. However, a variety of factors currently limit the immediate application of these exciting biomarkers. In this review, we provide a detailed rationalisation of the approach and basis for the use of methylation biomarkers for HCC detection and summarise recent studies on methylated DNA markers in HCC focusing on the importance of the aetiological cause of liver disease in the mechanisms leading to cancer.
引用
- Fu S, Debes JD, Boonstra A, et al. DNA methylation markers in the detection of hepatocellular carcinoma. Eur J Cancer. 2023. PMID: 37473464. doi:10.1016/j.ejca.2023.112960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。